It’s only been a few days since the FDA gave Amgen the green light to release its new migraine treatment, Aimovig, and the drug likely won’t have a corner on the market for long.
According to Teva Pharmaceuticals, its new migraine treatment, fremanezumab, is close to being approved by regulators as well. The company hopes it’ll get the nod by mid-September.
Eli Lilly also expects to get a decision from the FDA about its migraine drug, galcanezumab, later this year.
The medications belong to a new class of monoclonal antibodies that target a peptide that’is thought to play a role in producing migraines.
Migraines affect about 13 percent of Americans, but many of the current treatments are either ineffective or come with unpleasant side effects.
Read the full Reuters report.